{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:11:57Z","timestamp":1787026317954,"version":"build-2736575974"},"reference-count":70,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>\n                    Non-caseating granulomatous infiltration of the myocardium is the hallmark of cardiac sarcoidosis (CS). CS manifests clinically as conduction disturbance, ventricular arrhythmia, sudden cardiac death and\/or heart failure with reduced ejection fraction. Other than confirmation through endomyocardial biopsy, a diagnosis of probable CS can be established by histological evidence of systemic sarcoidosis in addition to characteristic clinical or advanced imaging findings. Cardiac Magnetic Resonance imaging (CMR) and\n                    <jats:sup>18<\/jats:sup>\n                    F-flurodeoxyglycose positron emission tomography (FDG-PET) are imaging modalities indispensable in the diagnosis and monitoring of CS. FDG-PET is the method of choice for identifying the active inflammatory phase of CS and in the monitoring and modifying of immunosuppressive treatment. CMR is better suited for assessing cardiac morphology and function. Both modalities are more effective in detecting CS when used in combination than either is alone. Management of CS is primarily based upon observational data of low quality due to a paucity of randomized controlled trials. Corticosteroid therapy and\/or tiered-immunosuppression are the mainstays of treatment in reducing myocardial inflammation. Steroid-sparing agents aim to limit the unfavorable side-effects of a significant steroid burden. Antiarrhythmics and guideline-directed medical therapies are utilized for control of ventricular arrhythmia and left ventricular dysfunction respectively. CS necessitates multidisciplinary care in specialized centers to most effectively diagnose and manage the disease. Additional randomized trials are warranted to further our understanding of medical optimization in CS.\n                  <\/jats:p>","DOI":"10.3389\/fcvm.2024.1394075","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:39:58Z","timestamp":1728347998000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Cardiac sarcoidosis: diagnosis and management"],"prefix":"10.3389","volume":"11","author":[{"given":"Abdullah","family":"Aftab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Szeto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoha","family":"Aftab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabahat","family":"Bokhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1056\/NEJMra2101555","article-title":"Challenges of sarcoidosis and its management","volume":"385","author":"Drent","year":"2021","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.114.011522","article-title":"Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study","volume":"131","author":"Kandolin","year":"2015","journal-title":"Circulation"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1007\/s12350-016-0658-1","article-title":"Isolated cardiac sarcoidosis: a focused review of an under-recognized entity","volume":"25","author":"Okada","year":"2018","journal-title":"J Nucl Cardiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"106864","DOI":"10.1016\/j.rmed.2022.106864","article-title":"Cardiac sarcoidosis outcome differences: a comparison of patients with de novo cardiac versus known extracardiac sarcoidosis at presentation","volume":"198","author":"Rosen","year":"2022","journal-title":"Respir Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1093\/eurheartj\/ehad067","article-title":"Cardiac sarcoidosis: phenotypes, diagnosis, treatment, and prognosis","volume":"44","author":"Lehtonen","year":"2023","journal-title":"Eur Heart J"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.hrthm.2014.03.043","article-title":"HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis","volume":"11","author":"Birnie","year":"2014","journal-title":"Heart Rhythm"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1253\/circj.cj-19-0508","article-title":"JCS 2016 guideline on diagnosis and treatment of cardiac sarcoidosis- digest version","volume":"83","author":"Terasaki","year":"2019","journal-title":"Circ J"},{"key":"B8","first-page":"19","article-title":"The WASOG sarcoidosis organ assessment instrument: an update of a previous clinical tool","volume":"31","author":"Judson","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"B9","article-title":"Cardiac sarcoidosis","volume-title":"StatPearls","author":"Hussain","year":"2023"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1016\/j.jacc.2020.08.042","article-title":"Challenges in cardiac and pulmonary sarcoidosis: a JACC state-of-the-art review","volume":"76","author":"Trivieri","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1111\/jce.15191","article-title":"Electrogram-guided endomyocardial biopsy yield in patients with suspected cardiac sarcoidosis and relation to outcomes","volume":"32","author":"Ezzeddine","year":"2021","journal-title":"J Cardiovasc Electrophysiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1342429","DOI":"10.3389\/fimmu.2023.1342429\/full","article-title":"Biomarkers and molecular endotypes of sarcoidosis: lessons from omics and non-omics studies","volume":"14","author":"Ji","year":"2024","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1536\/ihj.17-695","article-title":"A multiple biomarker approach in patients with cardiac sarcoidosis","volume":"59","author":"Kiko","year":"2018","journal-title":"Int Heart J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1136\/heartjnl-2015-307877","article-title":"Diagnosis and treatment of cardiac sarcoidosis","volume":"102","author":"Kusano","year":"2016","journal-title":"Heart Br Card Soc"},{"key":"B15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12872-019-01323-0","article-title":"Diagnostic and predictive value of speckle tracking echocardiography in cardiac sarcoidosis","volume":"20","author":"Di Stefano","year":"2020","journal-title":"BMC Cardiovasc Disord"},{"key":"B16","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/0002-9149(89)90323-8","article-title":"Two-dimensional echocardiographic findings in systemic sarcoidosis","volume":"63","author":"Burstow","year":"1989","journal-title":"Am J Cardiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/j.jacc.2005.01.047","article-title":"Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis","volume":"45","author":"Smedema","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1161\/CIRCULATIONAHA.109.851352","article-title":"Detection of myocardial damage in patients with sarcoidosis","volume":"120","author":"Patel","year":"2009","journal-title":"Circulation"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1093\/eurheartj\/ehi258","article-title":"Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies","volume":"26","author":"Mahrholdt","year":"2005","journal-title":"Eur Heart J"},{"key":"B20","volume-title":"Cardiac MRI vs. PET for the Evaluation of Cardiac Sarcoidosis: Consider MRI First","author":"Bravo","year":"2017"},{"key":"B21","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/RTI.0b013e3182761830","article-title":"Late gadolinium enhancement in cardiac sarcoidosis: characteristic magnetic resonance findings and relationship with left ventricular function","volume":"28","author":"Watanabe","year":"2013","journal-title":"J Thorac Imaging"},{"key":"B22","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1097\/00004728-200209000-00017","article-title":"Detection of myocardial involvement in patients with sarcoidosis applying T2-weighted, contrast-enhanced, and cine magnetic resonance imaging: initial results of a prospective study","volume":"26","author":"Vignaux","year":"2002","journal-title":"J Comput Assist Tomogr"},{"key":"B23","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jcmg.2012.10.021","article-title":"CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis","volume":"6","author":"Greulich","year":"2013","journal-title":"JACC Cardiovasc Imaging"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1136\/heartjnl-2013-305187","article-title":"Extensive late gadolinium enhancement on cardiovascular magnetic resonance predicts adverse outcomes and lack of improvement in LV function after steroid therapy in cardiac sarcoidosis","volume":"100","author":"Ise","year":"2014","journal-title":"Heart Br Card Soc"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1136\/jim-2016-000144","article-title":"Resolution of abnormal cardiac MRI T2 signal following immune suppression for cardiac sarcoidosis","volume":"64","author":"Crouser","year":"2016","journal-title":"J Investig Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12968-022-00866-0","article-title":"T2 mapping in myocardial disease: a comprehensive review","volume":"24","author":"O.Brien","year":"2022","journal-title":"J Cardiovasc Magn Reson"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1161\/circ.144.suppl_1.10664","article-title":"Abstract 10664: quantitative T2 mapping to diagnose cardiac sarcoidosis and predict incident heart failure","volume":"144","author":"Aquino","year":"2021","journal-title":"Circulation"},{"key":"B28","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s12350-017-1043-4","article-title":"A joint procedural position statement on imaging in cardiac sarcoidosis: from the cardiovascular and inflammation & infection committees of the European association of nuclear medicine, the European association of cardiovascular imaging, and the American society of nuclear cardiology","volume":"25","author":"Slart","year":"2018","journal-title":"J Nucl Cardiol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2967\/jnmt.113.132621","article-title":"18F-FDG PET and PET\/CT patient preparation: a review of the literature","volume":"42","author":"Surasi","year":"2014","journal-title":"J Nucl Med Technol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"omz033","DOI":"10.1093\/omcr\/omz033","article-title":"Spontaneous coronary artery dissection in cardiac sarcoidosis","volume":"2019","author":"Kandolin","year":"2019","journal-title":"Oxf Med Case Rep"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1007\/s12350-018-01582-y","article-title":"Diagnostic performance of F-18 FDG PET for detection of cardiac sarcoidosis; a systematic review and meta-analysis","volume":"27","author":"Kim","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.2967\/jnumed.117.196287","article-title":"Joint SNMMI\u2013ASNC expert consensus document on the role of 18F-FDG PET\/CT in cardiac sarcoid detection and therapy monitoring","volume":"58","author":"Chareonthaitawee","year":"2017","journal-title":"J Nucl Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"ehaa946.0286","DOI":"10.1093\/ehjci\/ehaa946.0286","article-title":"Prognostic role of positron emission tomography in patients with known or suspected cardiac sarcoidosis. a systematic review and meta-analysis","volume":"41","author":"Bhatia","year":"2020","journal-title":"Eur Heart J"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1007\/s12350-021-02684-w","article-title":"Localization of myocardial FDG uptake for prognostic risk stratification in corticosteroid-na\u00efve cardiac sarcoidosis","volume":"29","author":"Bekki","year":"2022","journal-title":"J Nucl Cardiol"},{"key":"B35","article-title":"Prognostic role of PET myocardial perfusion imaging in patients with cardiac sarcoidosis: a systematic review","author":"Ahmed","year":"","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"B36","volume-title":"FDG-PET is a Superior Tool in the Diagnosis and Management of Cardiac Sarcoidosis","author":"Bokhari","year":"2017"},{"key":"B37","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1007\/s12350-016-0399-1","article-title":"Diagnosis, therapeutic response assessment, and detection of disease recurrence in cardiac sarcoidosis: integral role of cardiac PET","volume":"23","author":"Cabrera","year":"2016","journal-title":"J Nucl Cardiol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1007\/s12350-018-01504-y","article-title":"The prognostic value of quantitating and localizing F-18 FDG uptake in cardiac sarcoidosis","volume":"27","author":"Flores","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s12350-013-9828-6","article-title":"Reduction in 18F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis","volume":"21","author":"Osborne","year":"2014","journal-title":"J Nucl Cardiol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e200112","DOI":"10.1148\/ryct.2021200112","article-title":"Trends in cardiovascular MRI and CT in the U.S. Medicare population from 2012 to 2017","volume":"3","author":"Goldfarb","year":"2021","journal-title":"Radiol Cardiothorac Imaging"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.3390\/ph14121286","article-title":"PET Imaging in cardiac sarcoidosis: a narrative review with focus on novel PET tracers","volume":"14","author":"Saric","year":"2021","journal-title":"Pharmaceuticals"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/ehjci\/jex146","article-title":"A joint procedural position statement on imaging in cardiac sarcoidosis: from the cardiovascular and inflammation & infection committees of the European association of nuclear medicine, the European association of cardiovascular imaging, and the American society of nuclear Cardiology","volume":"18","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"B43","first-page":"7","article-title":"Cardiac sarcoidosis: the role of cardiac MRI and 18F-FDG-PET\/CT in the diagnosis and treatment follow-up","volume":"30","author":"Al-Hayja","year":"2023","journal-title":"Br J Cardiol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2004079","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"Baughman","year":"2021","journal-title":"Eur Respir J"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e021183","DOI":"10.1161\/JAHA.121.021183","article-title":"Corticosteroid and immunosuppressant therapy for cardiac sarcoidosis: a systematic review","volume":"10","author":"Fazelpour","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"B46","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.amjcard.2004.08.083","article-title":"Prevention of left ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosis","volume":"95","author":"Chiu","year":"2005","journal-title":"Am J Cardiol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.amjcard.2022.04.051","article-title":"Effect of corticosteroids on left ventricular function in patients with cardiac sarcoidosis","volume":"177","author":"Wand","year":"2022","journal-title":"Am J Cardiol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.cardfail.2020.08.013","article-title":"Clinical and imaging response to tumor necrosis factor alpha inhibitors in treatment of cardiac sarcoidosis: a multicenter experience","volume":"27","author":"Gilotra","year":"2021","journal-title":"J Card Fail"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.15420\/cfr.2021.16","article-title":"Cardiac sarcoidosis: when and how to treat inflammation","volume":"7","author":"Giblin","year":"2021","journal-title":"Card Fail Rev"},{"key":"B50","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jacc.2016.03.605","article-title":"Cardiac sarcoidosis","volume":"68","author":"Birnie","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e010952","DOI":"10.1161\/jaha.118.010952","article-title":"Long-term corticosteroid-sparing immunosuppression for cardiac sarcoidosis","volume":"8","author":"Rosenthal","year":"2019","journal-title":"J Am Heart Assoc Cardiovasc Cerebrovasc Dis"},{"key":"B52","doi-asserted-by":"publisher","first-page":"518","DOI":"10.5603\/piap.2014.0069","article-title":"Methotrexate as a single agent for treating pulmonary sarcoidosis: a single centre real-life prospective study","volume":"82","author":"Goljan-Geremek","year":"2014","journal-title":"Pneumonol Alergol Pol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.2169\/internalmedicine.52.0976","article-title":"Usefulness of low-dose methotrexate monotherapy for treating sarcoidosis","volume":"52","author":"Isshiki","year":"2013","journal-title":"Intern Med Tokyo Jpn"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s12350-022-03171-6","article-title":"Prednisone vs methotrexate in treatment na\u00efve cardiac sarcoidosis","volume":"30","author":"Vis","year":"2023","journal-title":"J Nucl Cardiol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"427","DOI":"10.2169\/internalmedicine.53.0794","article-title":"Treatment with methotrexate and low-dose corticosteroids in sarcoidosis patients with cardiac lesions","volume":"53","author":"Nagai","year":"2014","journal-title":"Intern Med Tokyo Jpn"},{"key":"B56","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.ijcard.2018.11.131","article-title":"Treatment of cardiac sarcoidosis: a comparative study of steroids and steroids plus immunosuppressive drugs","volume":"276","author":"Ballul","year":"2019","journal-title":"Int J Cardiol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ijcard.2021.02.022","article-title":"Effectiveness and safety of infliximab in cardiac sarcoidosis","volume":"330","author":"Bakker","year":"2021","journal-title":"Int J Cardiol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.cardfail.2021.07.008","article-title":"Rituximab for the treatment of refractory cardiac sarcoidosis: a single-center experience","volume":"28","author":"Elwazir","year":"2022","journal-title":"J Card Fail"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/S0002-9149(01)01978-6","article-title":"Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone","volume":"88","author":"Yazaki","year":"2001","journal-title":"Am J Cardiol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"182","DOI":"10.15420\/aer.2020.09","article-title":"Management of cardiac sarcoidosis in 2020","volume":"9","author":"Gilotra","year":"2020","journal-title":"Arrhythmia Electrophysiol Rev"},{"key":"B61","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/cir.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"B62","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1093\/eurheartj\/ehz428","article-title":"Sudden death in cardiac sarcoidosis: an analysis of nationwide clinical and cause-of-death registries","volume":"40","author":"Ekstr\u00f6m","year":"2019","journal-title":"Eur Heart J"},{"key":"B63","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.amjcard.2022.03.038","article-title":"Meta-analysis of catheter ablation outcomes in patients with cardiac sarcoidosis refractory ventricular tachycardia","volume":"174","author":"Adhaduk","year":"2022","journal-title":"Am J Cardiol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1001\/jamacardio.2021.4738","article-title":"Outcomes associated with catheter ablation of ventricular tachycardia in patients with cardiac sarcoidosis","volume":"2","author":"Siontis","year":"2022","journal-title":"JAMA Cardiol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1161\/CIRCULATIONAHA.121.058120","article-title":"Incidence of sudden cardiac death and life-threatening arrhythmias in clinically manifest cardiac sarcoidosis with and without current indications for an implantable cardioverter defibrillator","volume":"146","author":"Nordenswan","year":"2022","journal-title":"Circulation"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1016\/j.jacc.2017.10.054","article-title":"2017 AHA\/ACC\/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines and the heart rhythm society","volume":"72","author":"Al-Khatib","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","article-title":"2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death","volume":"43","author":"Zeppenfeld","year":"2022","journal-title":"Eur Heart J"},{"key":"B68","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1093\/ehjci\/jex340","article-title":"Diagnostic accuracy and prognostic value of simultaneous hybrid 18F-fluorodeoxyglucose positron emission tomography\/magnetic resonance imaging in cardiac sarcoidosis","volume":"19","author":"Wicks","year":"2018","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"B69","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.jcmg.2021.08.018","article-title":"Hybrid cardiac magnetic resonance\/fluorodeoxyglucose positron emission tomography to differentiate active from chronic cardiac sarcoidosis","volume":"15","author":"Greulich","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"B70","volume-title":"Cardiac Sarcoidosis Multi-Center Randomized Controlled Trial","year":"2023"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1394075\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:40:03Z","timestamp":1728348003000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1394075\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":70,"alternative-id":["10.3389\/fcvm.2024.1394075"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2024.1394075","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,8]]},"article-number":"1394075"}}